KRAS Gene Mutation clinical trials at UC Cancer

1 research study open to eligible people

Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer
open to eligible people ages 18 years and up
Phase 1b/2 study to evaluate the FGFRi futibatinib in combination with the MEKi binimetinib in patients with advanced KRASmt tumors.
at UCLA

Our lead scientists for KRAS Gene Mutation research studies include Lee Rosen.

Last updated: March 22, 2023